ReviewAnnals of hematology2026
Re-treatment of relapse in elderly AML with time-limited venetoclax-based regimen: a case report and literature review.
Review in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Venetoclax and hypomethylating agent combination therapy is now the standard of care in acute myeloid leukemia (AML) for patients ineligible for intensive therapy, including the elderly; however, venetoclax and low-dose cytarabine remain a viable option for select patients. Relapse in this cohort remains a significant challenge, with a poor prognosis and an unmet need for further treatment options. This case discusses an elderly patient with NPM1-mutated AML successfully retreated with time-limited venetoclax and low-dose cytarabine at relapse. The sustained response observed contributes to the limited literature on the efficacy of re-treatment with venetoclax-based therapy in this setting. However, prospective data are required to assess the efficacy and safety of this strategy as well as to establish the role of molecular monitoring. The role of time-limited venetoclax therapy for preventing treatment resistance and limiting treatment-related adverse effects remains an important question in the cohort ineligible for intensive therapies, given the poor prognosis and limited options of relapsed/refractory AML post-venetoclax and hypomethylating agent therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.